Abstract

To observe and assess the effects of Sitagliptin monotherapy as initial therapy on pancreatic β cells function in recently diagnosed patients of type 2 Diabetes Mellitus. Methods: In this study 25 patients who were recently diagnosed as having type 2 DM were enrolled. Tab Sitagliptin 50 mg BD was administered to all patients enrolled. Laboratory investigations which were reflective of beta cell function namely C peptide level and serum insulin level were carried out in all the subjects and observed values were noted. Results: Fasting Serum Insulin and postprandial serum insulin levels were reduced significantly after 12 weeks of iniatiation of therapy. Significant reduction in fasting C-peptide as well as postprandial C-peptide was observed after 36 weeks in the sitagliptin treated patients. Conclusions: The results suggest treatment with sitagliptin 50 mg twice a day as initial therapy indeed has positive effect on increasing pancreatic beta cell function in recently diagnosed type 2 diabetes mellitus patients

Description